Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

849.99 +12.70 (+1.52%)
Official Closing Price Updated: 7:00 PM EDT, Jun 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,468,836
Open 837.76
Bid (Size) 850.50 (1)
Ask (Size) 855.00 (1)
Prev. Close 837.29
Today's Range 837.01 - 856.81
52wk Range 434.34 - 856.81
Shares Outstanding N/A
Dividend Yield 0.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Company Behind Mounjaro and Zepbound Is Sponsoring Caitlin Clark. Should You Buy the Stock?
One of the most lucrative sports sponsorship opportunities is jersey patches, and one leading pharmaceutical company may have just struck gold. 
Via The Motley Fool
Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm
You can use the wisdom of crowds and their fear and greed motives to profit from these three stocks to buy with plenty of room to run. 
Via InvestorPlace

Performance

YTD
+43.53%
+43.53%
1 Month
+9.68%
+9.68%
3 Month
+11.53%
+11.53%
6 Month
+42.13%
+42.13%
1 Year
+87.25%
+87.25%

More News

Read More
SPDR ETF Report For Friday, June 7
Via Talk Markets
Topics ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stocks Choppy As 'Higher for Longer' Fed Rhetoric Weighs
Via Talk Markets
Topics Economy
Exposures Interest Rates
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $700 Today
Via Benzinga
Over 10,000 Lawsuits In Novo Nordisk's Ozempic Case Assigned to New Judge
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Wall Street Reacts To Hot Jobs Report: Stocks Swing As Traders Abandon July Rate Cut Hopes
Via Benzinga
Stock Market Revs To Highs On Nvidia, CrowdStrike, Yields: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
Via Benzinga
Topics ETFs
Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits
Via Benzinga
Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance?
Via The Motley Fool
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Eli Lilly's Alzheimer's Drug, Donanemab Faces FDA's Adcomm Vote Next Week On Data, Risk Profile
Via Benzinga
Exposures Product Safety
Is Viking Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
Mid-Year Momentum Plays: 7 Stocks to Buy for the Second Half
Via InvestorPlace
Growth Stock Goliaths: 7 Picks That Will Tower Over the Competition
Via InvestorPlace
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Via Benzinga
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Via Benzinga
British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy
Via Benzinga
Google Parent Alphabet Appoints Eli Lilly's Finance Chief Ashkenazi As CFO
Via Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Via Investor's Business Daily
Alphabet Picks Eli Lilly Executive Anat Ashkenazi As New CFO
Via Investor's Business Daily
AMZN Buy Alert: Why Amazon Stock Is a Bargain Hiding in Plain Sight
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.